|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment显示文摘AIM:To compare the reliability of gastritis staging sys-tems in ranking gastritis-associated cancer risk in a large series of consecutive patients.METHODS:Gastric mucosal atrophy is the precancer-ous condition in which intestinal-type gastric cancer(GC)most frequently develops.The operative link for gas-tritis assessment(OLGA)staging system ranks the GC risk according to both the topography and the severity of gastric atrophy(as assessed histologically on the ba-sis of the Sydney protocol for gastric mucosal biopsy).Both cross-sectional and long-term follow-up trials have consistently associated OLGA stages Ⅲ-Ⅳ with a higher risk of GC.A recently-proposed modification of the OLGA staging system(OLGIM)basically incorporates the OLGA frame,but replaces the atrophy score with an assessment of intestinal metaplasia(IM)alone.A series of 4552 consecutive biopsy sets(2007-2009)was re-trieved and reassessed according to both the OLGA and the OLGIM staging systems.A set of at least 5 biopsy samples was available for all the cases considered.RESULTS:In 4460 of 4552 cases(98.0%),both the high-risk stages(Ⅲ + Ⅳ)and the low-risk stages(0 +Ⅰ + Ⅱ)were assessed applying the OLGA and OL-GIM criteria.Among the 243 OLGA high-risk stages,14(5.8%)were down-staged to a low risk using OLGIM.The 67(1.5%)incidentally-found neoplastic lesions(intraepithelial or invasive)were consistently associated with high-risk stages,as assessed by both OLGA and OLGIM(P < 0.001 for both).Two of 34 intestinal-type GCs coexisting with a high-risk OLGA stage(stage Ⅲ)were associated with a low-risk OLGIM stage(stage Ⅱ).CONCLUSION:Gastritis staging systems(both OLGA and OLGIM)convey prognostically important informa-tion on the gastritis-associated cancer risk.Because of its clinical impact,the stage of gastritis should be included as a conclusive message in the gastritis histol-ogy report.Since it focuses on IM alone,OLGIM staging is less sensitive than OLGA staging in the identif ication of patients at high risk of gastric cancer. | Massimo Rugge Matteo Fassan Marco Pizzi Fabio Farinati Giacomo Carlo Sturniolo Mario Plebani David Y Graham | 2011 | World Journal of Gastroenterology2011，17，41： | 19 |
| 2 | Role of blood AFP mRNA and tumor grade in the preoperative prognostic evaluation of patients with hepatoceiluiar carcinoma显示文摘AIM: To explore the potential prognostic role of preoperative tumor grade and blood AFP mRNA in a cohort of patients with hepatocellular carcinoma (HCC)eligible for radical therapies according to a well-defined treatment algorithm not including nodule size and number as absolute selection criteria.METHODS: Fifty patients with a diagnosis of HCC were prospectively enrolled in the study. Inclusion criteria were: (1) histological assessment of tumor grade by means of percutaneous biopsies; (2) determination of AFP mRNA status in the blood; (3) patient's eligibility for radical therapies.RESULTS: At preoperative evaluation, 54% of the study group had a well-differentiated HCC, 42% had AFP mRNA in the blood, 40% had a tumor larger than 5 cm and 56% had more than one nodule. Surgery (resection or liver transplantation) was performed in 29 patients,while 21 had percutaneous ablation procedures. After a median follow-up of 28 mo, 12-, 24-, and 36-mo survival rates were 78%, 58%, and 51%, respectively. Surgical therapy, performance status and three tumor-related variables (AFP mRNA, HCC grade and gross vascular invasion) resulted as significant survival predictors at univariate analysis. Nodule size and number did not perform as significant prognosticators. Multivariate study selected only surgical therapy and a biologically early HCC profile (AFP mRNA negative and well-differentiated tumor without gross vascular invasion) as independent survival variables.CONCLUSION: The preoperative determination of tumor grade and blood AFP mRNA status may potentially refine the prognostic evaluation of HCC patients and improve the selection process for radical therapies. | Umberto Cillo Alessandro Vitale Filippo Navaglia Daniela Basso Umberto Montin Marco Bassanello Francesco D'Amico Francesco Antonio Ciarleglio Alberto Brolese Giacomo Zanus Vito De Pascale Mario Plebani Davide Francesco D'Amico | 2005 | World Journal of Gastroenterology2005，11，44： | 12 |
| 3 | Is osteoporosis a peculiar association with primary biliary cirrhosis?显示文摘AIM: (1) To compare the prevalence of osteoporosis (t-score ≤-2.5 SD) between stage Ⅳ PBC patients, and two groups of age- and sex-matched controls: one with hepatitis C virus (HCV)-related cirrhosis, and the other one consisting of a group of healthy subjects from the general population; (2) to identify the main risk factors for the development of bone loss.METHODS: Thirty-five stage Ⅳ PBC patients (mean age 52.5±10 years), 49 females with HCV-related cirrhosis (mean age 52.9±5.8 years) and 33 healthy females (mean age 51.8+2.22 years) were enrolled in the study. Bone metabolism was evaluated by measuring serum calcium corrected for serum albumin (Ca corr.), 25-hydroxy vitamin D (25-OH vit D), parathyroid hormone, osteocalcin.Bone mineral density (BMD) was assessed at the lumbar spine by dual-photon X-ray absorptiometry.RESULTS: Osteoporosis was present in 5/35 PBC patients (14.2%) and in 7/49 HCV-related cirrhotic patients (14.3%),without any statistical difference between the two groups.Among healthy control subjects, none had osteoporosis.No difference was found between the three groups in serum parameters of bone metabolism. Univariate analysis showed that menopausal state and low BMI were significantly correlated with osteoporosis. Multivariate regression analysis showed that menopausal status, BMI <23, and old age were independent variables significantly correlated with osteoporosis.CONCLUSION: PBC in itself has no negative influence on BMD. End-stage liver disease patients carry a disease-specific risk for osteoporosis, but have an effective risk of bone loss in relation to individual potential risk for each patient. A practical message should be taken into account, that is, every effort should be made to prevent osteoporosis when a patient has simple osteopenia, or if it is a woman in or near menopausal age. | Annarosa Floreani Andrea Mega Valentina Camozzi Vincenzo Baldo Mario Plebani Patrizia Burra Giovanni Luisetto | 2005 | World Journal of Gastroenterology2005，11，34： | 7 |
| 4 | Diabetes mellitus and Parkinson's disease:dangerous liaisons between insulin and dopamine显示文摘The relationship between diabetes mellitus and Parkinson's disease has been described in several epidemiological studies over the 1960 s to date.Molecular studies have shown the possible functional link between insulin and dopamine,as there is strong evidence demonstrating the action of dopamine in pancreatic islets,as well as the insulin effects on feeding and cognition through central nervous system mechanism,largely independent of glucose utilization.Therapies used for the treatment of type 2 diabetes mellitus appear to be promising candidates for symptomatic and/or disease-modifying action in neurodegenerative diseases including Parkinson's disease,while an old dopamine agonist,bromocriptine,has been repositioned for the type 2 diabetes mellitus treatment.This review will aim at reappraising the different studies that have highlighted the dangerous liaisons between diabetes mellitus and Parkinson's disease. | Angela De Iuliis Ennio Montinaro Giuseppe Fatati Mario Plebani Carlo Colosimo | 2022 | Neural Regeneration Research2022，17，3： | 3 |
| 5 | Haemolysis: an overview of the leading cause of unsuitable specimens in clinical laboratories显示文摘 | Giuseppe Lippi Norbert Blanckaert Pierangelo Bonini Sol Green Steve Kitchen Vladimir Palicka Anne J. Vassault Mario Plebani | 2008 | Clinical Chemistry and Laboratory Medicine2008，，6： | 2 |
| 6 | Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C显示文摘 | Giada Sebastiani Alessandro Vario Maria Guido Franco Noventa Mario Plebani Roberta Pistis Alessia Ferrari Alfredo Alberti | 2006 | Journal of Hepatology2006，，4： | 2 |
| 7 | Erythrocyte Sedimentation Rate Use of Fresh Blood for Quality Control显示文摘 | Mario Plebani MD Elisa Piva | 2002 | Am J Clin Pathol2002，，117： | 1 |
| 8 | Precision performance at low levels and 99th percentile concentration of the Access<sup>?</sup> AccuTnI<sup>?</sup> assay on two different platforms显示文摘 | Martina Zaninotto Monica Maria Mion Enrica Novello Marco Moretti Ernesto Delprete Marco Bruno Rocchi Davide Sisti Mario Plebani | 2009 | Clinical Chemistry and Laboratory Medicine2009，，3： | 1 |
| 9 | The TEST - 1 Automated System A New Method For Measuring the Erythrocyte Sedimentation Rate显示文摘 | MARIO PLEBANI M D STEFANIA DE TONI M D | 1998 | American Journal of Clinical Pathology1998，11，3： | 1 |
| 10 | Determination of Sedimentation Reaction(Eryrhoncute Sedimentation Rate)in Non-Anticoagulated Blood wite the Microtest显示文摘 | Elisa Piva Paclo Fassina Mario Plebani | 2002 | Clin chem Lab Med2002，40，7： | 1 |
| 11 | ME-PCR for the identification of mutated K-ras in serum and bile of pancreatic cancer patients: an unsatisfactory technique for clinical applications显示文摘 | Carlo-Federico Zambon Filippo Navaglia Daniela Basso Nicoletta Gallo Eliana Greco Maria Grazia Piva Paola Fogar Claudio Pasquali Sergio Pedrazzoli Mario Plebani | 2000 | Clinica Chimica Acta2000，，1： | 1 |
| 12 | What is next in transla- tional medicine显示文摘 | Littman BH Mario LD Plebani M | 2007 | Clin Sci(Lond)2007，112，4： | 1 |
| 13 | How to use high-sensitivity cardiac troponins in acute cardiac care?显示文摘 | Kristian Thygesen Johannes Mair Evangelos Giannitsis Christian Mueller Bertil Lindahl Stefan Blankenberg Kurt Huber Mario Plebani Luigi M. Biasucci Marco Tubaro Paul Collinson Per Venge Yonathan Hasin Marcello Galvani Wolfgang Koenig Christian Hamm Joseph | 2012 | European Heart Journal2012，，18： | 1 |
| 14 | Non-invasive assessment of liver fibrosis: it is time for laboratory medicine显示文摘 | Giada Sebastiani Konstantinos Gkouvatsos Mario Plebani | 2011 | Clinical Chemistry and Laboratory Medicine2011，，1： | 1 |
| 15 | Preanalytical variability: the dark side of the moon in laboratory testing显示文摘 | Giuseppe Lippi Gian Cesare Guidi Camilla Mattiuzzi Mario Plebani | 2006 | Clinical Chemical Laboratory Medicine2006，，： | 1 |
| 16 | What's next in translational medicine? 显示文摘 | LITTMAN B H MARIO L D PLEBANI M | 2007 | Clin Sci (Lond)2007，112，21： | 1 |
| 17 | Errors in clinical laboratories or errors in laboratory medicine?显示文摘 | Mario Plebani | 2006 | Clinical Chemical Laboratory Medicine2006，，6： | 1 |
| 18 | Errors in clinical laboratories or errors in laboratory medicine显示文摘 | Mario Plebani | 2006 | Clin Chem Lab Med2006，44，6： | 1 |
| 19 | Non-invasive assessment of chronic liver and gastric diseases显示文摘 | Mario Plebani Daniela Basso | 2007 | Clinica Chimica Acta2007，，1： | 1 |
| 20 | High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome显示文摘 | Silvia Garelli Stefano Masiero Mario Plebani Shu Chen Jadwiga Furmaniak Decio Armanini Corrado Betterle | 2013 | European Journal of Obstetrics and Gynecology2013，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员